Key Highlights: Taisho Pharmaceutical secures exclusive rights to clinically develop, register, and commercialize Kaigene's next-generation FcRn inhibitor, KG006, in Japan. Kaigene will receive a $5 million upfront payment and is eligible for up to a combined total of $22 million and...
Hence then, the article about kaigene enters into exclusive licensing agreement with taisho pharmaceutical for next generation autoimmune asset kg006 in japan was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Kaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japan )
Also on site :
- Netflix sued for $105M by billionaire movie producer after his unreleased Nicolas Cage thriller goes missing
- Fiery crash snarls Highway 101 traffic in Novato
- 1943 Novella, Written During World War II, Named Among Books That 'Everyone Should Read At Least Once' on Goodreads